Time to readmission cut with injectable antipsychotics for patients with schizophrenia

Fewer patients on injectables needed medications to treat extrapyramidal symptoms, study shows.
HealthDay News

For those with schizophrenia or schizoaffective disorder, long-acting injectable antipsychotics show a significant reduction in 30-day readmission compared with oral antipsychotics,

US researchers found that the 30-day readmission rate was 2% for those discharged on long-acting injectable antipsychotic medications and 8% for the oral medications group.